The increasing use of immunophenotypic and molecular analysis in the routine evaluation of @entity1 with @entity6113 , @entity3329 , or other @entity1503 has led to the identification of unexpected small clonal lymphoid populations. These clones, sometimes with disease-specific markers, such as the t(14;18), are especially challenging for the clinician because of their unknown biologic potential and uncertain clinical behavior. Study of these early @entity706 is providing important clues to the process of lymphomagenesis, and may provide the rationale for preemptive therapy in the future. More and more, the hematologist/oncologist is consulted regarding otherwise healthy individuals with @entity6113 , and pathology reports that confound the referring internist or surgeon. The report does not name a @entity1071 , but is not completely "normal". Does the @entity1 have a benign or malignant condition? How should they be evaluated? Is treatment indicated? These @entity1 prove challenging for the consulting hematologist as well as the referring physician. In this review, we will focus on some of these scenarios and attempt to provide guidance for their management.

Lymphocytosis, XXXX : benign or malignant?

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity3329 :: ('MESH:D008206', 'Disease') :: ['lymphadenopathy'] @entity6113 :: ('MESH:D008218', 'Disease') :: ['lymphocytosis', 'lymphadenopathy and/or lymphocytosis'] @entity1071 :: ('MESH:D008232', 'Disease') :: ['malignant lymphoproliferative disorder'] @entity706 :: ('MESH:D008223', 'Disease') :: ['lymphoid lesions'] @entity1503 :: ('MESH:D006402', 'Disease') :: ['hematologic disorders']
@entity3329 :: (MESH:D008206,Disease) :: ['lymphadenopathy']
